How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
News headlines Recursion Pharmaceuticals has made significant strides in its AI-driven drug discovery platform, reporting promising clinical milestones. However, recent earnings revealed a 46.77% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results